Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

Xenobiotica

Volumn 39, Issue 5, 2009, Pages 407-414

  Fujiyama, N ^a   Miura, M ^a   Satoh, S ^a   Inoue, K ^a   Kagaya, H ^a   Saito, M ^b   Habuchi, T ^b   Suzuki, T ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carboxylesterase; Mycophenolic acid; Polymorphism; Renal transplantation

Indexed keywords

BENZYLSULFONYL FLUORIDE; BIS(4 NITROPHENYL) PHOSPHATE; CARBOXYLESTERASE; CARBOXYLESTERASE 2; DYFLOS; ESTERASE; INTESTINE ENZYME; LIVER ENZYME; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HYDROLYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; JAPANESE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER MICROSOME; MAJOR CLINICAL STUDY; REPEATED DRUG DOSE;

ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOXYLESTERASE; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOFLUROPHATE; KIDNEY TRANSPLANTATION; MICROSOMES, LIVER; MYCOPHENOLIC ACID; NITROPHENOLS; PHENYLMETHYLSULFONYL FLUORIDE; POLYMORPHISM, GENETIC; PREDNISOLONE; TACROLIMUS;

EID: 70350638932     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250902807338     Document Type: Article

References (33)

1. Armstrong VW, Tenderich G, Shipkova M, Parsa A, Koerfer R, Schroder H, Oellerich M. (2005). Pharmacokinetics and bio-availability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ter Drug Monit 27:315-321
2. Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D. (2007). C-440T/T-331C polymorphisms in the UGT1A9 gene afect the pharmacokinetics of myco-phenolic acid in kidney transplantation. Pharmacogenomics 8:1127-1141
3. Basu NK, Kole L, Kubota S, Owens IS. (2004). Human UDP- glucuronosyltransferases show atypical metabolism of myco-phenolic acid and inhibition by curcumin. Drug Metab Disposit 32:768-773
4. Bellott R, Le Morvan V, Charasson V, Laurand A, Colotte M, Zanger UM, Klein K, Smith D, Bonnet J, Robert J. (2008). Functional study of the 830C G polymorphism of the human carboxylesterase 2 gene. Cancer Chemother Pharmacol 61:481-488
5. Bernard O, Guillemette C. (2004). Te main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the efects of naturally occurring variants. Drug Metab Disposit 32:775-778
6. Bullingham RE, Nicholls AJ, Kamm BR. (1998). Clinical pharma-cokinetics of mycophenolate mofetil. Clinical Pharmacokinet 34:429-455
7. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J. (2004). Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ter 76:528-535
8. Heymann E, Krisch K. (1967). Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxyleste-rases. Hoppe-Seyler's Zeitschrift fur Physiologische Chemie 348:609-619
9. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, Satoh T. (1995). Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Disposit 23:1022-1027
10. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. (2000). Characterization of CPT-11 hydrolysis by human liver carboxy-lesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189-1192
11. Inoue K, Miura M, Satoh S, Kagaya H, Saito M, Habuchi T, Suzuki T. (2007). Infuence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacoki-netics in Japanese renal transplant recipients. Ter Drug Monit 29:299-304. (Pubitemid 47262259)
12. Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, et al. (2007). Infuence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:279-288 (Pubitemid 46233156)
13. Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, Habuchi T, Suzuki T. (2006). Quantifcation and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatogra-phy in Japanese renal transplant recipients. Yakugaku Zasshi 126:1357-1362
14. Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ter 106:97-132.
15. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. (2005). Te impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ter 78:351-361
16. Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL. (2004). Pharmacogenomic assessment of carboxy-lesterases 1 and 2. Genomics 84:661-668
17. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T. (2007). Infuence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharma-cokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:1161-1169 (Pubitemid 350112768)
18. Miura M, Satoh S, Niioka T, Kagaya H, Saito M, Hayakari M, Habuchi T, Suzuki T. (2008). Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ter Drug Monit 30:52-59
19. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. (2006). Multidrug resistance protein 2 genetic polymorphisms infu-ence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074-1084
20. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. (2005). Identifcation of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Disposit 33:139-146
21. Probst MR, Beer M, Beer D, Jeno P, Meyer UA, Gasser R. (1994). Human liver arylacetamide deacetylase. Molecular cloning of a novel esterase involved in the metabolic activation of arylamine carcinogens with high sequence similarity to hormone-sensitive lipase. J Biol Chem 269:21650-21656
22. Probst MR, Jeno P, Meyer UA. (1991). Purifcation and characterization of a human liver arylacetamide deacetylase. Biochem Biophys Res Comm 177:453-459
23. Roth D, Colona J, Burke GW, Ciancio G, Esquenazi V, Miller J. (1998). Primary immunosuppression with tacrolimus and mycophe-nolate mofetil for renal allograft recipients. Transplantation 65:248-252
24. Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K, Saito M, Inoue T, Miura M, Hayase Y, Suzuki T, Habuchi T. (2006). Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 82:486-493
25. Satoh T, Hosokawa M. (1998). Te mammalian carboxylesterases: from molecules to functions. Ann Rev Pharmacol Toxicol 38:257-288
26. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. (2002). Current progress on esterases: from molecular structure to function. Drug Metab Disposit 30:488-493
27. Schaub T P, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G, et al. (1999). Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10:1159-1169
28. Shaw LM, Holt DW, Oellerich M, Meiser B, Van Gelder T. (2001). Current issues in therapeutic drug monitoring of mycophe-nolic acid: report of a roundtable discussion. Ter Drug Monit 23.305-15
29. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. (1997). Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Disposit 25:1157-1164
30. Taketani M, Shii M, Ohura K, Ninomiya S, Imai T. (2007). Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci 81:924-932
31. Wu MH, Yan B, Humerickhouse R, Dolan ME. (2002). Irinotecan activation by human carboxylesterases in colorectal adenocar-cinoma cells. Clin Cancer Res 8:2696-2700
32. Xu G, Zhang W, Ma MK, McLeod HL. (2002). Human carboxyleste-rase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611
33. Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, et al. (2006). Involvement of human blood aryleste-rases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet 21:147-155